<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003890</url>
  </required_header>
  <id_info>
    <org_study_id>I125</org_study_id>
    <secondary_id>CAN-NCIC-IND125</secondary_id>
    <secondary_id>METHYL-MG98-002</secondary_id>
    <secondary_id>CDR0000067059</secondary_id>
    <nct_id>NCT00003890</nct_id>
  </id_info>
  <brief_title>MG98 in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Study of MG98 Given as a 2 Hour Twice Weekly IV Infusion in Patients With Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of MG98 in treating patients who have&#xD;
      advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of MG98 in patients with advanced solid tumors.&#xD;
&#xD;
        -  Assess the safety, toxicity, and pharmacokinetics of this treatment regimen in this&#xD;
           patient population.&#xD;
&#xD;
        -  Evaluate the effectiveness of this treatment regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation, multicenter study.&#xD;
&#xD;
      Patients receive MG98 IV over 2 hours twice weekly for 3 weeks. Courses are repeated every 4&#xD;
      weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      The dose of MG98 is escalated in cohorts of 1-6 patients until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6&#xD;
      patients experience dose limiting toxicity.&#xD;
&#xD;
      Patients are followed at week 4, then at least every 3 months until relapse of disease.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 20 patients will be accrued for this study within 10-12&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 22, 1999</start_date>
  <completion_date type="Actual">September 22, 2008</completion_date>
  <primary_completion_date type="Actual">September 27, 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">19</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MG 98</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically proven advanced solid tumor unresponsive to existing&#xD;
             therapy or for which no curative therapy exists&#xD;
&#xD;
          -  Evidence of disease in addition to tumor marker elevation&#xD;
&#xD;
          -  CNS metastases allowed, if adequately treated and symptoms controlled for greater than&#xD;
             4 months&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  PTT normal&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.25 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT or SGPT no greater than 3 times ULN (4 times ULN for liver metastases)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.25 times ULN&#xD;
&#xD;
          -  Proteinuria less than 2+ (no greater than 500 mg in a 24 hour urinalysis)&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other serious systemic disease&#xD;
&#xD;
          -  No known hypersensitivity to oligodeoxynucleotides&#xD;
&#xD;
          -  Adequate venous access&#xD;
&#xD;
          -  No known condition (e.g., psychological, geographical) that would prevent compliance&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after the&#xD;
             study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent colony stimulating factors unless evidence of neutropenic infection&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No more than 3 prior chemotherapy regimens&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  At least 1 year since prior high dose chemotherapy with bone marrow or stem cell&#xD;
             support&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Prior hormonal therapy allowed&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  Concurrent palliative radiotherapy allowed&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 2 weeks since prior major surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 3 weeks since prior investigational drug therapy&#xD;
&#xD;
          -  No other concurrent investigational drug or anticancer therapy&#xD;
&#xD;
          -  No concurrent coumadin or heparin therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ross C. Donehower, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Regional Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Stewart DJ, Donehower RC, Eisenhauer EA, Wainman N, Shah AK, Bonfils C, MacLeod AR, Besterman JM, Reid GK. A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Ann Oncol. 2003 May;14(5):766-74. doi: 10.1093/annonc/mdg216.</citation>
    <PMID>12702532</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 2, 2000</study_first_submitted>
  <study_first_submitted_qc>August 19, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2003</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

